Panbela Therapeutics Inc. (PBLA) concluded trading on Wednesday at a closing price of $1.36, with 3.95 million shares of worth about $5.38 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -95.47% during that period and on Wednesday the price saw a gain of about 20.35%. Currently the company’s 4.85M shares are available for trading.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 2 times over the past 12 months. They bought 0 shares in 0 of the transactions. In 2 selling transactions, insiders dumped 73,149 shares.
However, the stock later moved at a day high price of 1.4900, or with a gain of 20.35%. Stock saw a price change of 17.24% in past 5 days and over the past one month there was a price change of -85.63%. Year-to-date (YTD), PBLA shares are showing a performance of -92.57% which decreased to -99.84% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.06 but also hit the highest price of $930.00 during that period. The average intraday trading volume for Panbela Therapeutics Inc. shares is 715.26K. The stock is currently trading -51.70% below its 20-day simple moving average (SMA20), while that difference is down -86.18% for SMA50 and it goes to -97.46% lower than SMA200.
The stock has a current market capitalization of $6.61M and its 3Y-monthly beta is at 0.84. It has posted earnings per share of -$4016.17 in the same period. It has Quick Ratio of 0.21. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for PBLA, volatility over the week remained 13.91% while standing at 19.98% over the month.
Analysts are in expectations that Panbela Therapeutics Inc. (PBLA) stock would likely to be making an EPS of -$24.34 in the current quarter, while forecast for next quarter EPS is -$1.48 and it is -$34.38 for next year. For the current quarter EPS, analysts have given the company a lowest target -$28.4 which is -$20.28 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$3,408 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 94.53% while it is estimated to increase by 96.34% in next year.
